197 related articles for article (PubMed ID: 24785095)
1. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.
Sänger N; Ruckhäberle E; Bianchini G; Heinrich T; Milde-Langosch K; Müller V; Rody A; Solomayer EF; Fehm T; Holtrich U; Becker S; Karn T
Mol Oncol; 2014 Oct; 8(7):1196-207. PubMed ID: 24785095
[TBL] [Abstract][Full Text] [Related]
2. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
3. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
[TBL] [Abstract][Full Text] [Related]
4. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
5. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
6. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer.
Rachner TD; Kasimir-Bauer S; Göbel A; Erdmann K; Hoffmann O; Browne A; Wimberger P; Rauner M; Hofbauer LC; Kimmig R; Bittner AK
Clin Cancer Res; 2019 Feb; 25(4):1369-1378. PubMed ID: 30425091
[TBL] [Abstract][Full Text] [Related]
8. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.
Christoph F; König F; Lebentrau S; Jandrig B; Krause H; Strenziok R; Schostak M
World J Urol; 2018 Feb; 36(2):187-192. PubMed ID: 29204705
[TBL] [Abstract][Full Text] [Related]
9. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
10. Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.
Sarink D; Schock H; Johnson T; Overvad K; Holm M; Tjønneland A; Boutron-Ruault MC; His M; Kvaskoff M; Boeing H; Lagiou P; Papatesta EM; Trichopoulou A; Palli D; Pala V; Mattiello A; Tumino R; Sacerdote C; Bueno-de-Mesquita HBA; van Gils CH; Peeters PH; Weiderpass E; Agudo A; Sánchez MJ; Chirlaque MD; Ardanaz E; Amiano P; Khaw KT; Travis R; Dossus L; Gunter M; Rinaldi S; Merritt M; Riboli E; Kaaks R; Fortner RT
Cancer Prev Res (Phila); 2017 Sep; 10(9):525-534. PubMed ID: 28701332
[TBL] [Abstract][Full Text] [Related]
11. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
[TBL] [Abstract][Full Text] [Related]
12. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos J; Singer C; Narod SA
Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
[TBL] [Abstract][Full Text] [Related]
13. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.
Peng X; Guo W; Ren T; Lou Z; Lu X; Zhang S; Lu Q; Sun Y
PLoS One; 2013; 8(3):e58361. PubMed ID: 23516466
[TBL] [Abstract][Full Text] [Related]
15. The Relationship between Serum and Gene Expression Levels of RANK, RANKL and Osteoprotegerin Inflammatory Pathway with Unstable Angina: A Case-control Study.
Farrokhian A; Miraftab M; Chenari M; Akbari H; Nikoueinejad H; Naimi E
Iran J Allergy Asthma Immunol; 2021 Aug; 20(4):473-483. PubMed ID: 34418901
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
17. Bone destruction in chronic otitis media is not mediated by the RANKL pathway or estrogen receptor-alpha.
Heo KW; Noh M; Hur DY; Hong TU; Park SY; Kim WJ
Sci Prog; 2023; 106(3):368504231199204. PubMed ID: 37697808
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
19. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
20. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
